Nutramax is supporting clinical research of G/C efficacy
EDGEWOOD, Md. — Prominent health experts this past weekend provided updates on the use of glucosamine/chondroitin sulfate supplementation to maintain joint health at the Symptomatic Management of Osteoarthritis: New Evidence, presented at the Osteoarthritis Research Society International 2015 World Congress in Seattle on May 2, which was supported by Nutramax Laboratories Consumer Care.
"We salute Bioiberica, suppliers of the chondroitin sulfate used in CosaminDS, for assembling a world-class faculty for this symposium, which promises to generate an informative and provocative discussion of emerging clinical evidence," said Troy Henderson, president and CEO of Nutramax. "Our support of the symposium is in keeping with our efforts to advance the use of high-quality, pharmaceutical grade glucosamine/chondroitin sulfate supplements for joint health, and to encourage the industry's review of new evidence to affect change in clinical guidelines."
Nutramax recently announced plans to assemble a panel of joint health experts to review current American Academy of Orthopaedic Surgeons guidance on the use of glucosamine/chondroitin sulfate supplements for joint health. The panel will focus specifically on the most recent AAOS Evidence-based Guideline for using joint health supplements and provide its recommendation based on a growing body of clinical evidence, including data from the MOVES (Multicentre Osteoarthritis InterVEntion trial with Sysadoa) study, GAIT (Glucosamine/Chondroitin Arthritis Intervention Trial), and a multi-center Brazilian trial comparing CosaminDS (1,500 mg of glucosamine hydrochloride and 1,200 mg of chondroitin sulfate in capsule form) to a Brazilian prescription brand (1,500 mg of glucosamine sulfate and 1,200 mg of chondroitin sulfate) in either a sachet or a capsule formulation.
"We are excited to bring the very positive results from recent trials of glucosamine and chondroitin sulfate to a wider audience of clinicians," Henderson said. "We hope the Bioiberica symposium at OARSI 2015 stimulates a productive, long-term dialog with the AAOS and the rheumatology community as a whole."